Why the study?
Polymeric heart valves aim to combine bioprosthetic hemodynamics with mechanical valve longevity, motivating the development of a novel 3D-printable aortic valve prosthesis without a central metal leaflet restrictor.
Does the 3D-printed silicone TIPI 3.4 aortic valve prosthesis without a central metal restrictor structure improve in vitro hemodynamic performance (regurgitation fraction, systolic pressure gradient, and effective orifice area) compared to earlier prototypes and standard biological or mechanical prostheses?
Does the 3D-printed silicone TIPI 3.4 aortic valve prosthesis without a central metal restrictor structure improve in vitro hemodynamic performance (regurgitation fraction, systolic pressure gradient, and effective orifice area) compared to earlier prototypes and standard biological or mechanical prostheses?
A novel, restrictor-free 3D-printed silicone aortic valve prosthesis (TIPI 3.4) demonstrated in vitro hemodynamic performance comparable to a commercial mechanical valve, offering a simplified design potentially suitable for low-cost mass molding with biocompatible polymers.
Answers are grounded in this paper and cite their sources.
Advances 3D-printable polymeric aortic valves; leaves open durability, hemodynamics, and clinical translation.
(1) Background: Polymeric heart valves are prostheses constructed out of flexible, synthetic materials to combine the advantageous hemodynamics of biological valves with the longevity of mechanical valves. This idea from the early days of heart valve prosthetics has experienced a renaissance in recent years due to advances in polymer science. Here, we present progress on a novel, 3D-printable aortic valve prosthesis, the TIPI valve, removing the foldable metal leaflet restrictor structure in its center. Our aim is to create a competitive alternative to current valve prostheses made from flexible polymers. (2) Methods: Three-dimensional (3D) prototypes were designed and subsequently printed in silicone. Hemodynamic performance was measured with an HKP 2.0 hemodynamic testing device using an aortic valve bioprosthesis (BP), a mechanical prosthesis (MP), and the previously published prototype (TIPI 2.2) as benchmarks. (3) Results: The latest prototype (TIPI 3.4) showed improved performance in terms of regurgitation fraction (TIPI 3.4: 15.2 ± 3.7%, TIPI 2.2: 36.6 ± 5.0%, BP: 8.8 ± 0.3%, MP: 13.2 ± 0.7%), systolic pressure gradient (TIPI 3.4: 11.0 ± 2.7 mmHg, TIPI 2.2: 12.8 ± 2.2 mmHg, BP: 8.2 ± 0.9 mmHg, MP: 10.5 ± 0.6 mmHg), and effective orifice area (EOA, TIPI 3.4: 1.39 cm2, TIPI 2.2: 1.28 cm2, BP: 1.58 cm2, MP: 1.38 cm2), which was equivalent to currently used aortic valve prostheses. (4) Conclusions: Removal of the central restrictor structure alleviated previous concerns about its potential thrombogenicity and significantly increased the area of unobstructed opening. The prototypes showed unidirectional leaflet movement and very promising performance characteristics within our testing setup. The resulting simplicity of the shape compared to other approaches for polymeric heart valves could be suitable not only for 3D printing, but also for fast and easy mass production using molds and modern, highly biocompatible polymers.
No takes yet. Share an insight, caveat, or question.
Schröter et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: